Form 8-K

Zynex, Inc.

Date: April 23, 2013

/s/ Thomas Sandgaard

Thomas Sandgaard,

Chief Executive Officer

0001193125-13-172964.txt : 20130425 0001193125-13-172964.hdr.sgml : 20130425 20130425124324 ACCESSION NUMBER: 0001193125-13-172964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130422 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20130425 DATE AS OF CHANGE: 20130425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-26787-D FILM NUMBER: 13781933 BUSINESS ADDRESS: STREET 1: 9990 PARK MEADOWS DRIVE CITY: LONE TREE STATE: CO ZIP: 80124 BUSINESS PHONE: (303) 703-4906 MAIL ADDRESS: STREET 1: 9990 PARK MEADOWS DRIVE CITY: LONE TREE STATE: CO ZIP: 80124 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 8-K 1 d526948d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 22, 2013

Zynex, Inc.

(Exact name of Registrant as specified in its charter)


Nevada	33-26787-D	90-0275169
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

9990 Park Meadows Drive Lone Tree, Colorado		80124
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (303) 703-4906

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Kevin Smith as a Director

On April 22, 2013, Kevin Smith was appointed to the Board of Directors of Zynex, Inc. Mr. Smith will serve on the Board’s Audit Committee and its newly formed Compensation Committee.

Mr. Smith is the President and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4), a nonprofit focused on advancing the Colorado bioscience ecosystem through company creation and job growth. Prior to joining CID4, Mr. Smith was Managing Director of Act Three Consulting, LLC. Act Three was formed in July 2007 to provide consulting services to management teams and their advisors during times of dramatic change. Prior to founding Act Three until its acquisition by private equity investors in 2006, Kevin spent nine years as President of Gambro, Inc., the US holding company for Gambro AB, a manufacturer and distributer of cardiovascular, blood separation and renal dialysis products and the operator of kidney dialysis centers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.